Literature DB >> 29159873

Orthopaedic manifestations within the 22q11.2 Deletion syndrome: A systematic review.

Jelle F Homans1, Isabel N Tromp1, Dino Colo1, Tom P C Schlösser1, Moyo C Kruyt1, Vincent F X Deeney2, Terrence B Crowley3, Donna M McDonald-McGinn3,4, René M Castelein1.   

Abstract

The 22q11.2 Deletion Syndrome (22q11.2DS) is the most common microdeletion syndrome with an estimated prevalence of 1:4,000 live births. 22q11.2DS is known to have wide phenotypic variability, including orthopaedic manifestations. The purpose of this systematic review is to increase the awareness of orthopaedic manifestations associated with 22q11.2DS. This systematic review was performed according to the PRISMA Guidelines. Original epidemiological studies on the prevalence of orthopaedic manifestations within 22q11.2DS were systematically searched for in PubMed and EMBASE. The included articles were scored according to a risk-of-bias tool, a best-evidence synthesis was performed and the prevalence data was extracted. Sixty-nine published manuscripts described 58 orthopaedic manifestations in a total of 6,055 patients. The prevalence of at least one cervical or occipital anomaly is 90.5-100% (strong evidence). Fourteen studies (n = 2,264) revealed moderate evidence for a wide scoliosis prevalence of 0.6-60%. Two studies demonstrated that 5-6.4% of all 22q11.2DS patients required surgical scoliosis correction. Fifteen studies (n = 2,115) reported a 1.1-13.3% prevalence of clubfoot with moderate evidence. Other reported orthopaedic manifestations are patellar dislocation (10-20%), juvenile rheumatic arthritis (3.75%), impaired growth and skeletal anomalies like polydactyly (1.0-3.7%), syndactyly (11-11.8%), butterfly vertebrae (11.1%) and 13 ribs (2-19%). Orthopaedic findings are important manifestations of the 22q11.2DS, both in bringing patients to diagnostic attention and in requiring surveillance and appropriate intervention. Data on these manifestations are scattered and incomprehensive. Routinely screening for cervical anomalies, scoliosis, and upper and lower limb malformations is recommended in this vulnerable group of patients.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  22q11 Deletion syndrome; 22q11.2 Deletion syndrome; 22q11.2DS; DiGeorge syndrome; arthritis; cervical spine; clubfoot; extremities; growth; limb anomalies; orthopedics; scoliosis; spine; velocardiofacial syndrome

Mesh:

Year:  2017        PMID: 29159873     DOI: 10.1002/ajmg.a.38545

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  3 in total

1.  What is new with 22q? An update from the 22q and You Center at the Children's Hospital of Philadelphia.

Authors:  Ian M Campbell; Sarah E Sheppard; T Blaine Crowley; Daniel E McGinn; Alice Bailey; Michael J McGinn; Marta Unolt; Jelle F Homans; Erin Y Chen; Harold I Salmons; J William Gaynor; Elizabeth Goldmuntz; Oksana A Jackson; Lorraine E Katz; Maria R Mascarenhas; Vincent F X Deeney; René M Castelein; Karen B Zur; Lisa Elden; Staci Kallish; Thomas F Kolon; Sarah E Hopkins; Madeline A Chadehumbe; Michele P Lambert; Brian J Forbes; Julie S Moldenhauer; Erica M Schindewolf; Cynthia B Solot; Edward M Moss; Raquel E Gur; Kathleen E Sullivan; Beverly S Emanuel; Elaine H Zackai; Donna M McDonald-McGinn
Journal:  Am J Med Genet A       Date:  2018-10       Impact factor: 2.802

2.  Genotypic and phenotypic variability of 22q11.2 microdeletions - an institutional experience.

Authors:  Gabrielle C Manno; Gabrielle S Segal; Alexander Yu; Fangling Xu; Joseph W Ray; Erin Cooney; Allison D Britt; Sunil K Jain; Randall M Goldblum; Sally S Robinson; Jianli Dong
Journal:  AIMS Mol Sci       Date:  2021-12-09

3.  Prenatal Diagnosis of Talipes Equinovarus by Ultrasound and Chromosomal Microarray Analysis: A Chinese Single-Center Retrospective Study.

Authors:  Ruibin Huang; Xin Yang; Hang Zhou; Fang Fu; Ken Cheng; You Wang; Chunling Ma; Ru Li; Xiangyi Jing; Jin Han; Li Zhen; Min Pan; Dongzhi Li; Can Liao
Journal:  Genes (Basel)       Date:  2022-09-01       Impact factor: 4.141

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.